coagulation Flashcards
extrinsic pathway
plasma-mediated, initiation of hemostasis
AKA primary hemostasis
key: tissue factor
intrinsic pathway
amplifies and propogates hemostasis
aka secondary hemostasis
key: thrombin
common pathway
results in an insoluble fibrin clot
hemostasis is regulated by interactions between what three factors
vessel walls, circulating platelets, and clotting proteins in the plasma (FFP)
fibrinolysis definition
the orderly breakdown of a stable clot
in normal hemostasis what predominates - anticoagulants or procoagulants?
anticoagulants
what elicits vasoconstriction, the first step of the clotting pathway
damage to the endothelium that exposes the underlying ECM will elicit a contraction
also can be triggered by thrmobin, hypoxia, and high fluid sheer stress
what are the three major biochemical and physical change stages when forming a platelet plug
adhesion
activation
aggregation
thrombocytes
thrombus/clot + cells
what is the normal concentration of platelets per microliter
150,000-400,000
at what concentration of platelet per microliter do you start spontaneously bleeding and when is it lethal
<50,000 = spontaneous bleeding <10,000 = lethal
what is the life of a platelet
8-12 days (so you need to stop your antiplatelets for 8-12 days - or give them platelets)
platelet inhibitors
adenosine, insulin, NO, PGE2 and PGI2
platelet activators
adrenalin, cholesterol, thrombopoeitin, vWF, PGE2(viaEP3)
platelet adhesion
exposure to the subendothelial matrix proteins allows platelets to undergo a conformational change to adhere to the vascular wall
aka - matrix activates it and makes it sticky
von Willebrand factor
produced in the endothelium and platelets, released by endothelial cells and activated by platelets and its primary function is to bind other proteins
it is a bridging molecule between the subendothelial matrix and platelets forming crosslinks
GPIb-V-IX complex
binds vWF allowing platelet adhesion and platelet plug formation at sites of vascular injury
bernard soulier syndrome
absence of GPIb-V-IV receptor
when is vWB factor mainly activated
in conditions of high blood flow and shear stress
vWB disease
1 in 100 individuals are deficient but it is only clinically significant in 1 in 10,000
deficiency of vWB factor shows primarily in organs with small vessels and is diagnoses by measuring the amount of vWB factor in a vWB factor antigen assay and the funtionality of vWB factor wiht binding assays
factor 8 is also measured
type 1 vWB disease
60-80%
failure to secrete vWB factor into circulation or cleared too quickly
this is mild and often undiagnosed until bleeding following surgery, easy bruising, or menorrhagia
type 2 vWB disease
15-30%
this is a qualitative defect of the vWB factor and so effects vary
could have a decreased ability to either bind GPIb or VIII
type 3 vWB disease
most severe, homozygous defective gene, complete absence of production of vWB factor - leads to extremely low levels of factor VIII since it does not exsist to protect it from proteolytic degradation
platelet type vWB disease
in this type the problem is actually a defect of the platelet’s GPIb receptor
what are GPIIb/IIIa inhibitors?
they are a class of antiplatelets that block the ability of fibrinogen to form around aggregated platelets so no fibrinogen bridging of platelets to other platelets can occur
examples - abciximab (reopro), etifibatide (integrilin), tirofiban (aggrastat)
what is different about abciximab than other antiplatelets?
it irreversibly binds to its receptor so it takes 24hours to restore platelet function and is eliminated by plasma proteases
the other two (eptifibatide and tirofiban) reversibly bind to their receptors and it only takes 4-6 hours to restore platelet function and they are eliminated renally